Diagnosis, Risk Stratification, And Management Of Pulmonary Hypertension Of Sickle Cell Disease.
Key Points
Key Points
Observational studies have consistently shown that increased tricuspid regurgitant jet velocity (TRV) measured by Doppler echocardiography, an increased serum N-terminal pro–brain natriuretic peptide (NT-pro-BNP) level, and pulmonary hypertension measured by right heart catheterization are all independent risk factors for mortality in adults.
To reduce the variability and to improve the quality of care that patients with SCD receive, the ATS developed clinical practice guidelines to advise hematologists, pulmonologists, cardiologists, pediatricians, and internists about how to identify and manage patients with SCD who are at increased risk for mortality.
Diagnosis
...iagnos...
...fication guides clinical decision...
...ncreased risk for mortality is def...
...Sample Questions for Evaluation of Dyspne...
...Proposed Algorithm for Evaluation of P...
...re 2. Echocardiogram of a Patient with Pulmonary...
Treatment
...reatment...
...atients with SCD who have an increased ris...
...h SCD who have an increased risk for mort...
...patients with SCD who have RHC-confirmed PH, ve...
...ents with SCD who have elevated TRV al...
...tients with SCD who have RHC-confirmed PH,...
...elect patients with SCD who have RHC-confirm...
...ts with SCD who have RHC-confirmed marked...
...tionsHaving trouble viewing table? Expand...